Table 2.
Treatment outcomes of HMT according to TET2 mutation status.
| Variables | WT TET2 (n = 30) | Mutant TET2 (n = 11) | p-Value |
|---|---|---|---|
| Any response to HMT | 25 (83.3) | 9 (81.8) | 1.000 |
| Hematologic improvement | |||
|
20 (66.7) | 6 (54.5) | 0.491 |
|
21 (70.0) | 5 (45.5) | 0.272 |
| Disease progression | 19 (63.3) | 3 (27.3) | 0.040 |
| Median time to progression (m) * | 19.3 (5.5–47.8) | 49.8 (6.7–95.9) | 0.007 |
| Leukemic transformation | 17 (56.7) | 2 (18.2) | 0.029 |
| Death | 23 (76.7) | 4 (36.4) | 0.026 |
Abbreviations: HMT, hypomethylating therapy; m, month; TET2, Tet methylcytosine dioxygenase 2; WT, wild-type. * Median time to progression was calculated with Kaplan–Meier method using intention-to-treat (ITT) analysis. A log-rank test was used to compare TTP.